CINECA IRIS Institutional Research Information System

CREPALDI, Tiziana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.953
EU - Europa 2.824
AS - Asia 1.461
SA - Sud America 23
OC - Oceania 22
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 20
Totale 8.324
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.852
CN - Cina 817
IE - Irlanda 429
IT - Italia 411
SE - Svezia 407
DE - Germania 348
UA - Ucraina 258
FR - Francia 223
SG - Singapore 214
FI - Finlandia 201
GB - Regno Unito 174
KR - Corea 165
AT - Austria 102
DK - Danimarca 102
CA - Canada 96
VN - Vietnam 74
JP - Giappone 58
PL - Polonia 58
IN - India 41
ID - Indonesia 27
RU - Federazione Russa 27
ES - Italia 25
BE - Belgio 24
EU - Europa 20
AU - Australia 17
BR - Brasile 15
NL - Olanda 14
HK - Hong Kong 13
TW - Taiwan 13
SN - Senegal 11
TH - Thailandia 8
TR - Turchia 8
MY - Malesia 7
IR - Iran 6
CH - Svizzera 5
MX - Messico 5
NZ - Nuova Zelanda 5
CL - Cile 3
CZ - Repubblica Ceca 3
PH - Filippine 3
SK - Slovacchia (Repubblica Slovacca) 3
AE - Emirati Arabi Uniti 2
AR - Argentina 2
BO - Bolivia 2
ET - Etiopia 2
HU - Ungheria 2
NO - Norvegia 2
PK - Pakistan 2
RO - Romania 2
SA - Arabia Saudita 2
BG - Bulgaria 1
BW - Botswana 1
BY - Bielorussia 1
CO - Colombia 1
EG - Egitto 1
IL - Israele 1
LU - Lussemburgo 1
MA - Marocco 1
MU - Mauritius 1
NA - Namibia 1
NG - Nigeria 1
PT - Portogallo 1
TG - Togo 1
ZM - Zambia 1
Totale 8.324
Salva come PNG Salva come JPEG
Città #
Chandler 706
Beijing 590
Dublin 429
Ann Arbor 334
Houston 222
Jacksonville 181
Nyköping 159
Fairfield 153
Singapore 147
Ashburn 145
Torino 142
Medford 122
Villeurbanne 121
Princeton 105
Wilmington 105
Vienna 102
Dearborn 88
Woodbridge 71
Toronto 67
Milan 66
Fremont 59
Dong Ket 54
Warsaw 52
Cambridge 49
Boardman 41
Seattle 41
Pisa 40
Verona 39
Guangzhou 37
Jakarta 27
Turin 26
Boston 24
New York 20
Brussels 19
Lachine 19
Falls Church 18
Nanjing 17
Redwood City 17
Santa Clara 17
Norwalk 16
Hefei 14
Shanghai 14
Munich 13
Los Angeles 12
Kunming 11
Pune 11
Madrid 10
Hangzhou 8
Auburn Hills 7
London 7
San Mateo 7
Wuhan 7
Hebei 6
Nuillé-sur-vicoin 6
Nürnberg 6
San Diego 6
Seoul 6
Tokyo 6
Zhengzhou 6
Central District 5
Chengdu 5
Hsinchu 5
Leeds 5
Montrouge 5
Nanchang 5
Phoenix 5
Shenzhen 5
Sydney 5
Xian 5
Zhenjiang 5
Amsterdam 4
Auburn 4
Central 4
Dallas 4
Elche 4
Frankfurt am Main 4
Fuzhou 4
Goiânia 4
Harbin 4
Helsinki 4
Jinan 4
Mountain View 4
Nuremberg 4
Qingdao 4
Rome 4
Tianjin 4
University Park 4
Uppsala 4
Bangkok 3
Brisbane 3
Bydgoszcz 3
Chicago 3
Colton 3
Edmonton 3
Florence 3
Guiyang 3
Lappeenranta 3
Osaka 3
Paris 3
Philadelphia 3
Totale 5.013
Salva come PNG Salva come JPEG
Nome #
MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine 283
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) 253
Transgenic models of cardiac cachexia and cardiac effects of muscular atrophy 220
Ghrelin and Des-Acyl Ghrelin Promote Differentiation and Fusion of C2c12 Skeletal Muscle Cells 201
Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes 195
Sustained Met signalling in the heart leads to cardiac compensated hypertrophy and remodelling, which evolves into congestive heart failure 177
Ghrelin induces differentiation and fusion of C2C12 myoblasts and protects myotubes from atrophy 176
Activated Met Signalling in the Developing Mouse Heart Leads to Cardiac Disease 170
A New Transgenic Mouse Model of Heart Failure and Cardiac Cachexia Raised by Sustained Activation of Met Tyrosine Kinase in the Heart 157
Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy 155
Hepatocyte growth factor regulates migration of olfactory interneuron precursors in the rostral migratory stream through Met-Grb2 coupling. 126
Equine T lymphocytes express MHC class II antigens. 122
Conditional activation of met in differentiated skeletal muscle induces atrophy 115
Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma 114
[Analysis of a sample of the Italian population for HLA-DR antigen. Gene frequencies and gametic associations] 112
[Association between HLA antigens and juvenile dermatitis herpetiformis] 110
Gene expression profiling of HGF/Met activation in neonatal mouse heart 105
A xenogeneic monoclonal antibody recognizing specificities controlled by HLA-A and B alleles. 104
HGF receptor agonists protect cardiomyocytes from CoCl2-induced cell injury 103
Cellular and molecular mechanisms of HGF/Met in the cardiovascular system 102
Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib 100
RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis 99
Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma 98
HGF/Met tyrosine kinase receptor in heart physiology and pathophysiology 94
[Preliminary serological analysis for identification of direct monoclonal antibodies against surface structures of HLA typed human lymphocytes] 93
HGF-mediated modulation of Connexin 43 in cardiac cells 93
An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors 91
ERK: A key player in the pathophysiology of cardiac hypertrophy 91
Mek1 inhibition in vivo mitigates progressive cardiac concentric hypertrophy promoted by activated Met receptor. 90
Cardiac glycosides as new modulators of cholesterol metabolism 88
Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes 88
Chronic active hepatitis B. Interferon-activated natural killer-like cells against a hepatoma cell line transfected with the hepatitis B virus nucleic acid. 88
Conditional expression of the Met oncogene in skeletal muscle induces severe atrophy in mice 88
Characterization by monoclonal antibodies of lymphocyte subsets present in B-enriched suspensions. 87
RNAI AS A TOOL TO SUPPRESS TPR-MET MEDIATED TUMORIGENESIS 86
The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes 86
Conditional expression of activated met in differentiated skeletal muscle induces atrophy 86
Alloantisera with apparent HLA-A specificity reacting only against phytohemagglutinin-activated cells. 84
HGF receptor agonists protect cardiomyocytes from CoCl2-induced cell injury 82
Identification of novel circulating microRNAs in advanced heart failure by next-generation sequencing 82
Factor XII protects neurons from apoptosis by epidermal and hepatocyte growth factor receptor-dependent mechanisms 81
Met activation for cardioprotection against anthracycline cardiotoxicity. 79
Cytolitic activity of monoclonal antibodies strongly depends on rabbit complement used. 77
Digoxin and ouabain induce the efflux of cholesterol via LXR signalling and the synthesis of ATP in cardiomyocytes. 77
C-terminal truncated forms of Met, the hepatocyte growth factor receptor. 76
Activation of the MET receptor attenuates doxorubicin-induced cardiotoxicity in vivo and in vitro 75
New mouse models to study HGF/Met role in postnatal heart development and heart disease pathogenesis 74
Signaling to cardiac hypertrophy: insights from human and mouse RASopathies 72
Met activation for cardioprotection against anthracyclines cardiotoxicity 71
Emerging role of hepatocyte growth factor in cardiac function 70
Cardiac expression of hepatocyte growth factor increases adultneovascularization 70
HGF/c-Met in postnatal heart development 70
Cardiac glycosides modulate cholesterol metabolism via SREBP-2 and LXR activation 70
[Current status of research on specific monoclonal xenoantibodies against human histocompatibility antigens] 67
Analysis of Mlc-lacZ Met mutants highlights the essential function of Met for migratory precursors of hypaxial muscles and reveals a role for Met in the development of hyoid arch-derived facial muscles 67
Conditional expression of hepatocyte growth factor in cardiac and skeletal muscle for regeneration studies 66
Gain-of-function mouse models of the hgf/met axis reveal cardiac defects 66
Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. 65
New mouse models to study pathological consequences of chronical activation of HGF/c-MET axis specifically in the heart 65
A mouse model for spatial and temporal expression of HGF in the heart 65
[Polymorphic determinants of HLA-A, B molecules analysed with monoclonal antibodies: serologic characterization and evaluation of technical variations] 64
Molecular engineering strategies tailoring the apoptotic response to a met therapeutic antibody 64
The monoclonal antibody AC1.59 defines a new polymorphic determinant on HLA-DR molecules. 63
PAX3-FKHR at the cross-road between differentiation and transformation 63
TRUNCATED FORMS OF THE HEPATOCYTE GROWTH FACTOR (HGF) RECEPTOR 63
Quantitative expression of HLA class I molecules in acute non-lymphoblastic leukaemia cells. 62
Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. 61
Conditional expression of hepatocyte growth factor in cardiac and skeletal muscle for regeneration studies 61
The long-lasting protective effect of HGF in cardiomyoblasts exposed to doxorubicin requires a positive feed-forward loop mediated by ERK1,2-TIMP1-STAT3 61
A new duplication at the C4B locus associated with the HLA-Aw68, Cw8, Bw65 haplotype. 60
HGF/Met Axis in Heart Function and Cardioprotection 60
Selective expression of the Met/HGF receptor in human central nervous system microglia 60
Activated human T cells express beta 2-microglobulin-associated HLA-A,B,C molecules not recognized by W6/32 mAb. 59
HGF/Met axis has anti-apoptotic and anti-autophagic function in hypoxic cardiac injury 59
Cardiac expression of hepatocyte growth factor increases adult neovascularization 58
Emerging role of hepatocyte growth factor in cardiac function 57
New HLA class I-like alloantigens expressed on blast cells. 55
Contribution of monoclonal antibodies to the study of HLA class I antigens. 55
[Different cytotoxic reactivity of anti-HLA A or B sera against sub-population of human lymphocytes prepared with different methods] 55
Inhibition of DNA replication and growth of several human and murine neoplastic cells by aphidicolin without detectable effect upon synthesis of immunoglobulins and HLA antigens. 54
Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells. 54
Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor 54
Identification of anti-DQ alloantisera correlated with DR5. 53
IEF analysis of HLA molecules immunoprecipitated by putative anti-class I-like alloantisera. 53
HGF and MET: From Brain Development to Neurological Disorders 53
HLA class I- like antigen expression on human leukemic cells. 51
New HLA antigenic determinant shared by A2 and a subtype of Bw16 molecules detected by a monoclonal antibody. 50
Effect of hepatocyte growth factor on assembly of zonula occludens-1 protein at the plasma membrane. 49
Mice with inducible cardiomyocyte expression of hepatocyte growth factor develop sistoli contractile dysfunction 49
Expression of class I-like alloantigens on leukemic cells is not correlated with the amount of HLA-A,B,C molecules. 48
Novel therapy for myocardial infarction: can HGF/Met be beneficial? 47
Expression of HLA class I antigens in human tumors and their involvement in tumor growth. 47
Further antigenic determinants on HLA-A molecules. 46
Overexpression of the Met/HGF receptor in ovarian cancer. 46
The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. 45
Generation of a truncated hepatocyte growth factor receptor in the endoplasmic reticulum 42
Hepatocyte growth factor acts as a motogen and guidance signal for gonadotropin hormone-releasing hormone-1 neuronal migration 36
Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor. 34
Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. 34
Anti-met fab-fc for the treatment of a tumor and/or metastasis 30
Totale 8.432
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.819
article - articoli 0
book - libri 0
conference - conferenze 7.020
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.839
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020946 0 0 63 86 85 160 125 60 149 110 70 38
2020/2021884 72 69 62 42 91 36 80 14 141 75 67 135
2021/20221.179 63 71 46 72 63 49 97 56 39 77 310 236
2022/20231.970 207 193 45 185 198 500 114 105 232 65 81 45
2023/2024762 130 165 32 47 35 105 32 34 8 33 52 89
2024/2025211 15 132 64 0 0 0 0 0 0 0 0 0
Totale 8.637